|In Vitro||et al., bioRxiv, doi:10.1101/2021.05.05.442779 (Preprint) (In Vitro)||in vitro||ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation|
|In Vitro study and animal study showing that ProLung™-budesonide inhibits SARS-CoV-2 replication (results for budesonide were not provided). ProLung™-budesonide and budesonide significantly decreased lung inflammation. ProLung™-budesonide..|
|Late||et al., medRxiv, doi:10.1101/2021.04.10.21254672 (Preprint)||hosp./death, ↓17.5%, p=0.24||Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial|
|Interim results from the PRINCIPLE trial, 751 treated with budesonide starting a median of 6 days after symptom onset, showing lower hospitalization/death, and faster recovery with treatment.|
|Early||et al., Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00160-0 (preprint 2/8) (Peer Reviewed)||hosp./ER, ↓81.8%, p=0.02||Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial|
|RCT with 73 budesonide patients and 73 control patients, showing significantly lower combined risk of an ER visit or hospitalization, and lower risk of no recovery at day 14.|
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary; multiple approaches are required to protect all people from all existing and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.